Treatment of Polycythemia Vera With Gleevec
NCT01120821 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2010-05-17
Summary
The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.
Conditions
Interventions
- DRUG
-
Gleevec
400 mg once daily for 12 months
Sponsors & Collaborators
-
Weill Medical College of Cornell University
lead OTHER
Principal Investigators
-
Richard Silver, M.D. · Weill Medical College of Cornell University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-08-31
- Primary Completion
- 2007-01-31
- Completion
- 2007-06-30
Countries
- United States
Study Locations
More Related Trials
-
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
NCT05353647 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
NCT03401112 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
NCT05481151 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
NCT04293185 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
NCT04628585 ·Status: ENROLLING_BY_INVITATION
-
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
NCT02151526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
NCT05445128 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
NCT06752746 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
NCT04983264 ·Status: COMPLETED ·Phase: PHASE1
-
Real-world Ruxolitinib Experience in PV
NCT06251102 ·Status: NOT_YET_RECRUITING
-
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
NCT07012109 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
RH Genotype Matched RBC Transfusions
NCT04156893 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
NCT01745120 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients
NCT05791591 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
SMYLS Multi-site Trial
NCT06035939 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
NCT04182100 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
NCT02212535 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Hydroxyurea and Transfusion
NCT03644953 ·Status: COMPLETED ·Phase: PHASE2
-
SMYLS: A Self-management Program for Youth Living With Sickle Cell Disease
NCT04289311 ·Status: COMPLETED ·Phase: NA
-
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
NCT00230165 ·Status: RECRUITING
-
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
NCT05036512 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
NCT01895361 ·Status: COMPLETED ·Phase: PHASE2